NOVEL RESPIRABLE RIFAMPICIN-CURCUMIN LOADED NANOPARTICLES AGAINST Mycobacterium tuberculosis INFECTION

MARTINENA C; PALMA S; ALARCON L; MARTÍN C; DONNOLI L; RIEMER C; RIEDEL J; MORELLI P; PELLEGRINI J; AMIANO N; BERNABEU E; GARCÍA V; CHIAPETTA D; MORETTON M; TATEOSIAN NL

Modalidad Virtual

Congreso; LXVIII REUNIÓN ANUAL DE SLXVIII REUNIÓN ANUAL DE LA SOCIEDAD ARGENTINA DE INMUNOLOGÍA; 2020

Sociedad Argentina de Inmunología

Rifampicin (RIF) is one of the most powerful and effective first line drug employedin the treatment of Mycobacterium tuberculosis (Mtb) infection. With the worldwideemergence of highly drug-resistant tuberculosis (TB), novel agents that have directantimycobacterial effects or that enhance host immunity are urgently needed. Itwas described the immunomodulatory anti-TB effects of Curcumin (CUR), a potentanti-oxidant and apoptosis inducer compound. We develop novel RIF-CURnanoparticles (RIF-CUR NP) with improved drug aqueous solubility and stability forinhalator administration. Then, we analyzed by confocal microscopy the in vitrouptake of CUR-NP (20 µg/ml) in human macrophages (derived from PBMCs) atdifferent time points (1h, 18h, 24h and 48h). We found a higher drug cellularuptake levels (intensity/ area) for Mtb antigen-stimulated cells (0.25±0.04) thanunstimulated control (0.07±0.02) over 18 hours (ANOVA test, p